Web17 mrt. 2016 · The ATM inhibitor Ku55993 (Merck) was used at 10 µM and replenished every 24 hr. For DNA damage induction, NSCs of the indicated genotypes were either left untreated or subjected to 0.8 Gy irradiation or 2 mM hydroxyurea (HU) and harvested after 1 hr and 3 hr respectively for RNA extraction or protein lysates. Web28 mei 2024 · M1774 is a potent, selective, orally administered ATR inhibitor that has been shown to exert antitumor activity in patient-derived xenograft tumors and acute myeloid …
Sotirios Sotiriou – Head of Biology / Co-Founder
Web12 apr. 2024 · Merck KGaA, Darmstadt, Germany, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia … Web12 feb. 2024 · M3541 is an orally administered selective inhibitor of ATM. Methods. This phase I dose-escalation study evaluated the maximum-tolerated dose (MTD), … 5命班尼特武器
LYNPARZA® (olaparib) Receives Three New Approvals in Japan - Merck
Web30 mrt. 2024 · Gupta S, Halabi S, Kemeny G, Anand M, Giannakakou P, Nanus DM, George DJ, Gregory SG, Armstrong AJ. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Mol Cancer Res. 2024 Jun;19(6):1040-1050. doi: 10.1158/1541-7786.MCR-20-0975. Epub … Web24 jan. 2024 · Germany’s Merck KGaA (MRK: DE) says it has entered into an exclusive licensing agreement with Vertex Pharmaceuticals (Nasdaq: VRTX) for two DNA-dependent protein kinase (DNA-PK) inhibitors - M9831 (formerly known as VX-984) and an additional pre-clinical compound - in the field of gene editing for six specific genetic disease … Web24 apr. 2024 · AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced further positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation … 5和5s屏幕通用吗